{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:45:13Z","timestamp":1792154713763,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T00:00:00Z","timestamp":1548201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Chimerix Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.antiviral.2019.01.008","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T01:35:13Z","timestamp":1548034513000},"page":"50-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review"],"prefix":"10.1016","volume":"163","author":[{"given":"Roy F.","family":"Chemaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1544-9903","authenticated-orcid":false,"given":"Sebastian","family":"Voigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl S.","family":"Peggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2019.01.008_bib1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0166-3542(00)00070-X","article-title":"Antiviral activity of ganciclovir elaidic acid ester against herpesviruses","volume":"45","author":"Andrei","year":"2000","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib3","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/BF02116525","article-title":"Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus","volume":"14","author":"Andrei","year":"1995","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis. Offic. Publ. Eur. Soc. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.09.004","article-title":"Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review","volume":"342","author":"Ariza-Heredia","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.antiviral.2019.01.008_bib5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11908-012-0292-2","article-title":"Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment","volume":"14","author":"Beam","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.antiviral.2019.01.008_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the management of cytomegalovirus infection","volume":"26","author":"Bowman","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.antiviral.2019.01.008_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S0024-3205(01)01213-9","article-title":"The potency of acyclovir can be markedly different in different cell types","volume":"69","author":"Brand","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.antiviral.2019.01.008_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1086\/518514","article-title":"Cytomegalovirus UL97 kinase mutations that confer maribavir resistance","volume":"196","author":"Chou","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.008_bib9","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.3390\/v6114731","article-title":"KSHV targeted therapy: an update on inhibitors of viral lytic replication","volume":"6","author":"Coen","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.01.008_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(05)67176-0","article-title":"Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial","volume":"366","author":"Dondorp","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.01.008_bib11","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","article-title":"Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial","volume":"376","author":"Dondorp","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2019.01.008_bib12","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J. Clin. Virol.Offic. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.antiviral.2013.08.024","article-title":"Baseline sensitivity of HSV-1 and HSV-2 clinical isolates and defined acyclovir-resistant strains to the helicase-primase inhibitor pritelivir","volume":"100","author":"Field","year":"2013","journal-title":"Antivir. Res."},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2019.01.008_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/ajt.12112","article-title":"Adenovirus in solid organ transplantation","volume":"13","author":"Florescu","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib15","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1128\/AAC.00214-13","article-title":"Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97","volume":"57","author":"Gentry","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib16","series-title":"Vistide\u00ae (Cidofovir Injection) US Prescribing Information","author":"Gilead","year":"2010"},{"key":"10.1016\/j.antiviral.2019.01.008_bib17","first-page":"2774","article-title":"Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir","volume":"37","author":"Gordon","year":"1996","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"10.1016\/j.antiviral.2019.01.008_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1128\/AAC.00046-11","article-title":"CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes","volume":"55","author":"Gosert","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.008_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2004.10.003","article-title":"Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity","volume":"65","author":"Hartline","year":"2005","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: orthopox-, adeno-, and herpesviruses","volume":"159","author":"Hartline","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib22","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2019.01.008_bib23","doi-asserted-by":"crossref","first-page":"e1980","DOI":"10.1002\/rmv.1980","volume":"28","author":"Hiwarkar","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1167\/iovs.10-5671","article-title":"In vitro synergism of trifluorothymidine and ganciclovir against HSV-1","volume":"52","author":"Hobden","year":"2011","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"10.1016\/j.antiviral.2019.01.008_bib25","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2017.06.008","article-title":"Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34(+) selected hematopoietic cell transplantation","volume":"23","author":"Huang","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/bmt.2010.201","article-title":"Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT","volume":"46","author":"Ishiyama","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-3062.2011.00662.x","article-title":"Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation","volume":"14","author":"Ishiyama","year":"2012","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.008_bib29","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1128\/AAC.00837-10","article-title":"Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures","volume":"54","author":"Jiang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib30","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2018.09.016","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: polyomaviruses and lymphotropic herpesviruses","volume":"159","author":"Keith","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib32","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib33","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","article-title":"In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication","volume":"49","author":"Kern","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib34","article-title":"Acyclovir in the treatment of herpes viruses - a review","volume":"25","author":"Klysik","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.antiviral.2019.01.008_bib35","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.3390\/v2122740","article-title":"Development of CMX001 for the treatment of poxvirus infections","volume":"2","author":"Lanier","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2019.01.008_bib36","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/AAC.46.3.762-768.2002","article-title":"Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines","volume":"46","author":"Leary","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib37","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/ajt.14282","article-title":"BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the Swiss Transplant Cohort Study","volume":"17","author":"Leboeuf","year":"2017","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12977","article-title":"Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients","author":"Lee","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.antiviral.2019.01.008_bib39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1128\/CMR.00116-13","article-title":"Adenovirus infections in immunocompetent and immunocompromised patients","volume":"27","author":"Lion","year":"2014","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.01.008_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jcv.2006.06.012","article-title":"Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation","volume":"37","author":"Loginov","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib42","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/00002030-199711000-00006","article-title":"In Vitro Antiviral Drug Sensitivity of the Kaposi's Sarcoma-Associated Herpesvirus","volume":"11","author":"Medveczky","year":"1997","journal-title":"AIDS (Lond. Engl.)"},{"key":"10.1016\/j.antiviral.2019.01.008_bib43","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40265-018-0943-1","article-title":"New developments in the management of cytomegalovirus infection after transplantation","volume":"78","author":"Meesing","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.antiviral.2019.01.008_bib44","series-title":"PREVYMIS\u2122 (Letermovir) US Prescribing Information","author":"Merck","year":"2017"},{"key":"10.1016\/j.antiviral.2019.01.008_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcv.2009.05.017","article-title":"Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate","volume":"46","author":"Milbradt","year":"2009","journal-title":"J. Clin. Virol. Offic. Publ. Pan Am. Soc. Clin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib46","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.49.3.1010-1016.2005","article-title":"Antiadenovirus activities of several classes of nucleoside and nucleotide analogues","volume":"49","author":"Naesens","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/bmt.2012.121","article-title":"Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephalitis following antiviral prophylaxis","volume":"48","author":"Ogata","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib48","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1705907","article-title":"Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation","volume":"41","author":"Ogata","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib49","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bbmt.2018.02.008","article-title":"Effects of prophylactic foscarnet on human herpesvirus-6 reactivation and encephalitis in cord blood transplant recipients: a prospective multicenter trial with an historical control group","volume":"24","author":"Ogata","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib50","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1128\/AAC.02814-14","article-title":"In vitro efficacy of brincidofovir against variola virus","volume":"58","author":"Olson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/ndt\/gfv392","article-title":"Perception, diagnosis and management of BK polyomavirus replication and disease in paediatric kidney transplant recipients in Europe","volume":"31","author":"Pape","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.antiviral.2019.01.008_bib52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5045\/br.2015.50.4.194","article-title":"Hematopoietic stem cell expansion and generation: the ways to make a breakthrough","volume":"50","author":"Park","year":"2015","journal-title":"Blood Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib53","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1128\/JCM.03274-15","article-title":"Novel method based on real-time cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus","volume":"54","author":"Piret","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.coviro.2014.09.019","article-title":"The development of new therapies for human herpesvirus 6","volume":"9","author":"Prichard","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/CMR.00015-13","article-title":"Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation","volume":"26","author":"Razonable","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2019.01.008_bib56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.01800-13","article-title":"Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells","volume":"58","author":"Sharma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib57","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1128\/AAC.03714-14","article-title":"Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells","volume":"58","author":"Sharma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib58","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1128\/AAC.23.5.676","article-title":"Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine","volume":"23","author":"Smee","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/QAD.0b013e32835a9b16","article-title":"Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women","volume":"27","author":"Stier","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2019.01.008_bib60","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0166-0934(94)90041-8","article-title":"A sensitive assay system screening antiviral compounds against herpes simplex virus type 1 and type 2","volume":"49","author":"Sudo","year":"1994","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.antiviral.2019.01.008_bib61","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0166-0934(91)90136-N","article-title":"In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus","volume":"35","author":"Tatarowicz","year":"1991","journal-title":"J. Virol Methods"},{"key":"10.1016\/j.antiviral.2019.01.008_bib62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1574-6968.1988.tb02753.x","article-title":"The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG)","volume":"49","author":"Taylor","year":"1988","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.antiviral.2019.01.008_bib63","series-title":"Bailey and Scott's Diagnostic Microbiology","author":"Tille","year":"2013"},{"key":"10.1016\/j.antiviral.2019.01.008_bib64","series-title":"Poster Presented at the American Association of Pharmaceutical Scientists Annual Meeting","article-title":"Tissue distribution of radioactivity after intravenous and oral administration of [14C]brincidofovir to rats","author":"Tippin","year":"2016"},{"key":"10.1016\/j.antiviral.2019.01.008_bib65","first-page":"291","article-title":"Letermovir treatment of human cytomegalovirus infection antiinfective agent","volume":"38","author":"Verghese","year":"2013","journal-title":"Drugs Future"},{"key":"10.1016\/j.antiviral.2019.01.008_bib66","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/sj.cgt.7700638","article-title":"Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs","volume":"10","author":"Wildner","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.antiviral.2019.01.008_bib67","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib68","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2019.01.008_bib69","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.antiviral.2011.03.184","article-title":"Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation","volume":"90","author":"Wolf","year":"2011","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2019.01.008_bib70","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1128\/JVI.73.9.7271-7277.1999","article-title":"Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole","volume":"73","author":"Zacny","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2019.01.008_bib71","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1021\/jm900126v","article-title":"(Z)- and (E)-2-(1,2-dihydroxyethyl)methylenecyclopropane analogues of 2'-deoxyadenosine and 2'-deoxyguanosine. Synthesis of all stereoisomers, absolute configuration, and antiviral activity","volume":"52","author":"Zhou","year":"2009","journal-title":"J. Med. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218306570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:28:28Z","timestamp":1759062508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218306570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":71,"alternative-id":["S0166354218306570"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}